IVVD Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of 27.14%. Invivyd, Inc.'s return on equity of -87.85% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 255.87%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that Invivyd, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Invivyd, Inc. is more attractive than ADMA Biologics, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Invivyd, Inc.'s net income of -$10.5M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 7.44x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of -30201.66%. Invivyd, Inc.'s return on equity of -87.85% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 255.87%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.29%. Given that Invivyd, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Invivyd, Inc. is more attractive than Cidara Therapeutics, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Invivyd, Inc.'s net income of -$10.5M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 7.44x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of -255.85%. Invivyd, Inc.'s return on equity of -87.85% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 255.87%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Invivyd, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Invivyd, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Invivyd, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Invivyd, Inc.'s net income of -$10.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 7.44x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -79.75% compared to Invivyd, Inc.'s net margin of -3135.32%. Invivyd, Inc.'s return on equity of -87.85% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Invivyd, Inc. has a consensus price target of $10.00, signalling upside risk potential of 255.87%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that Invivyd, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Invivyd, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Invivyd, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Invivyd, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Invivyd, Inc. quarterly revenues are $13.1M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Invivyd, Inc.'s net income of -$10.5M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Invivyd, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd, Inc. is 7.44x versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.